Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 880 results found. Search for [ life sciences ]

Results 1 to 21 of 880
PTI
August 8, 2020
The drug is being made available to over 1,000 hospitals providing COVID-19 treatment in India through the company's distribution network, Jubilant Life Sciences said in a statement


Jeff Maggioncalda, CEO, Coursera
New Delhi, August 5, 2020
Digital technologies will fill the gaps in our education system, be it virtual field trips, use of AR/VR in experiments or online lessons on-the-go


BusinessToday.In
August 4, 2020
Stocks to watch today on August 4: Yes Bank, Jubilant Life, Exide, Bank of India, Dhanlaxmi Bank among others are the top stocks to watch out for in Tuesday's trading session.


PTI
August 4, 2020
On July 20, 2020, the company received approval from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19


Rukmini Rao
July 30, 2020
The growth was negated with double digit decline in travel and hospitality, retail and consumer goods, which the company expects to be under pressure for the rest of the year as well


Prasanna Mohanty
July 27, 2020
Profit-driven enterprises are ill-suited to protect the health and life of a vast majority of people, as the US and Indian governments experience, but do precious little, thereby failing in their primary duty


BusinessToday.In
July 27, 2020
The stock price of Karur Vysya Bank trades higher than 50 and 100 day but lower than 5, 20 and 200-day moving averages. Karur Vysya Bank stock has risen after 3 days of consecutive fall. Market capitalisation of the lender stood at Rs 2.449.80 crore as of today's session.


PB Jayakumar
July 23, 2020
Way back in early March, Thermo Fisher was among the first two companies to receive emergency use authorisation from the US Food and Drug Administration (USFDA) to start making RT-PCR kits for COVID-19 testing


PTI
July 23, 2020
Testing facility, which was inaugurated by Ladakh Lieutenant Governor R K Mathur, is capable of screening 50 samples per day, says defence ministry


BusinessToday.In
July 23, 2020
Coronavirus (Covid-19) Vaccine News Latest Updates: Head of WHO's emergencies programme Mike Ryan has said that while there are multiple contenders and many companies have made significant progress, the likely time for a coronavirus vaccine in the market is not before 2021


Chitranjan Kumar
July 22, 2020
Jhunjhunwala raised his holding in Rallis India, Federal Bank, Edelweiss Financial Services, NCC, Jubilant Life Sciences, Delta Corp and Firstsource Solutions (FSL), while cut his stake in Lupin and Agro Tech Foods


BusinessToday.In
July 22, 2020
The small cap share gained up to 4.85% to Rs 187.90 against previous close of Rs 179.20 on BSE


Anand Adhikari
New Delhi, July 22, 2020
A slowing economy and widespread stress in India Inc. are creating opportunities for promoters and strategic investors to ink M&As, buy back shares and delist


BusinessToday.In
July 22, 2020
Coronavirus (COVID-19) Vaccine News Latest Updates: Dr Cyrus Poonawalla, Chairman of the Poonawalla Group, says a just a few million doses of the potential COVID-19 vaccine will not be enough and the company intends to manufacture around 1 billion doses after getting all the necessary approvals


BusinessToday.In
July 21, 2020
The pharma share gained up to 4.44% to Rs 753.4 against previous close of Rs 721.50 on BSE


BusinessToday.In
July 21, 2020
Stock Market Highlights on July 21: ICICI Bank, followed by Maruti, Kotak Bank, Axis Bank, Power Grid and HDFC Bank were among the top gainers today, while Bajaj Finserv and ITC were the top laggards.


BusinessToday.In
July 21, 2020
Stocks to watch today on July 21: IndiGo, SBI Cards, ACC, Indian Oil, Jubilant Life among others are the top stocks to watch out for in Tuesday's trading session.


BusinessToday.In
July 20, 2020
Remdesivir is one of the few medicines believed to be effective in treating coronavirus patients. So far, it has secured approvals for emergency use from US FDA and conditional approval from the European Commission.


Rajeev Dubey
New Delhi, July 17, 2020
Sharks in the pharma supply chains are stockpiling and black-marketing a key life-saving drug for Covid-19, an India Today investigation has found. Remdesivir, produced by America's Gilead Sciences, is touted as the best hope for critically-ill coronavirus patients for its ability to shorten recovery times in clinical trials. India Today's undercover investigation has found that those who need remdesivir to keep them alive may not be able to afford it because of its excessive pricing on the black market. But, who's at fault? Rajeev Dubey, Editor, Business Today explains.Also Read: Coronavirus vaccine update: COVAXIN human trials start at PGI Rohtak


Rukmini Rao
July 17, 2020
The company also said the decline in the revenue was not just due to COVID-19, but also because of  large off shoring of deals signed last year


PAGES 1 OF 44  12345